Heron Therapeutics Inc
AXD2
Company Profile
Business description
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Contact
100 Regency Forect Drive
Suite 300
CaryNC27518
USAT: +1 858 251-4400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
122
Stocks News & Analysis
stocks
ASX healthcare share remains undervalued ahead of earnings
Margin recovery remains the key driver for this ASX healthcare share.
stocks
Alphabet earnings: Strong AI monetization continues to spearhead results
We maintain our fair value estimate for wide-moat Alphabet.
stocks
AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event
We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,963.40 | 10.80 | -0.12% |
| CAC 40 | 8,299.09 | 138.80 | -1.64% |
| DAX 40 | 24,763.12 | 392.29 | -1.56% |
| Dow JONES (US) | 51,711.65 | 506.93 | -0.97% |
| FTSE 100 | 10,639.17 | 77.80 | -0.73% |
| HKSE | 24,873.51 | 337.30 | -1.34% |
| NASDAQ | 25,137.69 | 553.21 | -2.15% |
| Nikkei 225 | 64,396.59 | 2,026.01 | -3.05% |
| NZX 50 Index | 13,757.51 | 37.80 | -0.27% |
| S&P 500 | 7,408.30 | 90.66 | -1.21% |
| S&P/ASX 200 | 8,793.00 | 2.70 | -0.03% |
| SSE Composite Index | 3,849.76 | 27.01 | -0.70% |